
Zunairah Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11919233/publications.pdf Version: 2024-02-01



7ιινιαίολη ζηλη

#	Article	IF	CITATIONS
1	Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. Antibodies, 2022, 11, 22.	1.2	1
2	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 741-751.	0.2	5
3	Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma. Journal of Hematology (Brossard, Quebec), 2021, 10, 89-97.	0.4	5
4	Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma—All That Glitters Is Not Gold. JAMA Oncology, 2021, 7, 967.	3.4	0
5	Outcomes of Haploidentical Stem Cell Transplantation in Patients with Fanconi Anemia; A Systematic Review. Blood, 2021, 138, 4308-4308.	0.6	0
6	Evidence-based supportive care in multiple myeloma. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 313-317.	0.4	1
7	Interventions to Reduce Stigma Related to Mental Illnesses in Educational Institutes: a Systematic Review. Psychiatric Quarterly, 2020, 91, 887-903.	1.1	44
8	Small Intestinal Tumors: A Rare Case of Tubulovillous Adenoma in Duodenum. Cureus, 2019, 11, e4671.	0.2	1
9	Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review. Blood, 2018, 132, 5742-5742.	0.6	6
10	The Use of Checkpoint Inhibitors before and after Allogeneic Stem Cell Transplantion: A Double-Edged Sword. Blood, 2018, 132, 5722-5722.	0.6	1
11	A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma. Blood, 2018, 132, 5639-5639.	0.6	2
12	Histone Deacetylase Inhibitors in Myelodysplastic Syndrome. Blood, 2018, 132, 5528-5528.	0.6	1
13	Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 5640-5640.	0.6	2
14	Efficacy and Safety of Histone Deacetylase Inhibitors in Multiple Myeloma - a Systematic Review of Early Phase Clinical Trials. Blood, 2018, 132, 5629-5629.	0.6	1
15	Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 3292-3292.	0.6	0
16	Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review. Blood, 2018, 132, 3309-3309.	0.6	0
17	Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review. Blood, 2018, 132, 1948-1948.	0.6	0
18	Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials. Blood, 2018, 132, 5659-5659.	0.6	0

ZUNAIRAH SHAH

#	Article	IF	CITATIONS
19	Evidence Based Recommendations for Supportive Care in Multiple Myeloma. Blood, 2018, 132, 1952-1952.	0.6	Ο
20	Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review. Blood, 2018, 132, 1949-1949.	0.6	0
21	Efficacy and Safety Profile of Novel Alkylators in Combination Regimens for Patients with Multiple Myeloma: A Review of Literature. Blood, 2018, 132, 5626-5626.	0.6	Ο
22	Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature. Blood, 2018, 132, 5624-5624.	0.6	0
23	Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis. Blood, 2018, 132, 5779-5779.	0.6	Ο
24	Efficacy and Safety of Newer Targeted Immunotherapy for Multiple Myeloma. Blood, 2018, 132, 5650-5650.	0.6	0